TTY Biopharm Co. Ltd.

Lipid nanoparticles (LNPs) have become a powerful tool for delivering drugs and genes. This technology has been instrumental in the development of various cancer treatments and vaccines, including those for COVID-19. LNPs are also being explored for use in vaccines against other infectious diseases, demonstrating their broad potential in improving human health. Lipid nanoparticles (LNPs) are being investigated as a game-changer in drug delivery for a wide range of pharmaceuticals, from tiny molecules to complex biologicals. The key advantage lies in their ability to overcome challenges faced by traditional drug delivery methods. This makes some of us ask this question - what are Lipid nanoparticles? What are Lipid nanoparticles? Lipid nanoparticles (LNPs) are microscopic spheres of fatty molecules (lipids). They act as Trojan horses, carrying drugs or genetic material like messenger RNA (mRNA) inside them. LNPs are a promising tool in medicine because they can address some of the challenges medications face when entering the body. LNPs are typically between 10 and 1000 nanometers in diameter. A nanometer is one-billionth of a meter. LNPs are made of various lipids, including cholesterol, phospholipids, and ionizable lipids. These lipids help to stabilize the LNP and allow it to fuse with cells. What are the different types of the lipid nanoparticles market Liquid Lipid-Core LNP, Solid Lipid-Core LNP (Solid Lipid Nanoparticle), Nanostructured Lipid Carrier (NLC), Hollow LNPs are types of the lipid nanoparticles. There are also other emerging LNP types, such as liposomes (early versions of LNPs) and some hybrid variations. These may be used for specific applications or offer unique properties. This is the largest segment and focuses on LNPs used to deliver drugs for various diseases like cancer, infectious diseases, and others. Explore the Demo Study @ 1.Liquid Lipid-Core LNP Liquid Lipid-Core LNPs have a core composed of liquid lipids. This liquid can be arranged in various structures, including liquid crystalline phases. The shape and structure of lipid nanoparticles (LNPs) depend on the ingredients used and how they're made. Traditionally, scientists create LNPs by mixing water and oil solutions with a helper molecule (surfactant) using machines like high-pressure homogenizers or sound waves (ultrasonication). Alternatively, they can use solvents to separate and then combine the components 2. Solid Lipid-Core LNP These LNPs have a solid lipid core that can encapsulate both hydrophilic (water-loving) and hydrophobic (water-fearing) drugs. They offer good stability and controlled release properties but may have limitations in drug loading capacity. 3.Nanostructured Lipid Carrier (NLC) NLCs have a core matrix made from a blend of solid and liquid lipids, rather than just solid lipids like in SLNs. This unique structure offers some advantages. NLCs potentially hold more medication compared to SLNs due to the presence of liquid lipids. Additionally, the ability to control the ratio of solid and liquid lipids allows researchers to tailor NLCs for controlled drug release or targeting specific tissues. Read our related market research report’s key insights: Lipid Nanoparticles (LNPs) CDMO Market Lipid Nanoparticle Raw Materials Market Lipid-Nanoparticle Based Genomic Medicines Market Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Nanoparticle Formulation Market mRNA Treatment Market So, what are the market dynamics of the lipid nanoparticles industry? Key Market Driving Factors: Advancements in Drug Delivery Technology Growing Demand for Innovative Therapeutics Rising Investment in R&D Success of LNP-based Therapies Focus on Addressing Challenges COVID-19 Vaccine Development Increasing Prevalence of Chronic Diseases Biocompatibility and Safety Patent Expirations and Generic Drugs Rising Healthcare Expenditure Market Restraints: High Production Costs Complex Formulation Process Limited Expertise and Technical Knowledge Stability and Shelf-life Concerns Competition from Alternative Technologies Trends: Expansion of mRNA-Based Therapeutics Gene Editing and Gene Therapy Targeted Drug Delivery Biodegradable and Sustainable LNPs The lipid nanoparticles sector is highly specialized, competitive and rapidly growing. Johnson & Johnson, Sun Pharmaceutical, CSPC, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Echelon Biosciences, BroadPharm, Biopharma PEG Scientific Inc., NOF AMERICA CORPORATION, CordenPharma, International, Merck KGaA, Avanti Polar Lipids, Tebubio, Creative Biolabs are some of the prominent players in the industry. This can be attributed to the effectiveness of lipid nanoparticles in cancer treatment and the commercial success of recently developed screening tool for evaluating mRNA enclosed in lipid nanoparticle. In February 2024, University of Pennsylvania researchers in the United States have developed a unique high-throughput screening tool designed for evaluating mRNA enclosed in lipid nanoparticles. With the help of this cutting-edge platform, large libraries of LNPs intended for brain targeting may be quickly screened. Its application accelerates the development of gene editing treatments by assessing and fine-tuning LNPs meant for brain delivery. Similarly, in July 2023, a formulation technique from Cytiva has been made available to enable the seamless production of lipid nanoparticle medications at both the clinical and commercial stages. By streamlining the procedure, this method makes it possible to produce lipid nanoparticle-based drugs effectively and completely, from development to commercialization. Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com

药械追踪 Products 01 全球首个胰岛素生物类似药，礼来优泌安在中国获批上市 近日，礼来宣布旗下甘精胰岛素获国家药监局批准上市，用于需用胰岛素治疗的成人1型和2型糖尿病，青少年和年龄在6岁及以上儿童的1型糖尿病，商品名优泌安。 优泌安是全球首个胰岛素生物类似药，也是目前全球应用最广泛的胰岛素生物类似药，与原研甘精胰岛素具有相同的氨基酸序列和药物剂型。与传统胰岛素相比，长效人胰岛素类似物（甘精胰岛素）比中效胰岛素等治疗药物在降低患者夜间低血糖发生率、控制空腹血糖等方面更具优势。 02 基石药业与泛生子联合开发泰吉华伴随诊断试剂盒在华获批上市 近日，基石药业宣布，公司与北京泛生子基因科技有限公司合作开发的泰吉华（通用名：阿伐替尼）伴随诊断试剂盒“人PDGFRA基因D842V突变检测试剂盒”获国家药监局批准，成为中国伴随诊断试剂指导原则出台后批准的首个以桥接路径合作开发的伴随诊断试剂盒，可通过检测胃肠间质瘤患者的PDGFRA基因突变，用于泰吉华药物的伴随诊断。 该试剂盒是首个结合中国境内外药效数据批准上市的国产伴随诊断试剂盒；首个在《抗肿瘤药物的非原研伴随诊断试剂临床试验注册审查指导原则》和《与抗肿瘤药物同步研发的原研伴随诊断试剂临床试验注册审查指导原则》出台后以完整桥接路径上市的伴随试剂盒；首个药物和伴随诊断均获得国家药监局优先审评的案例。 03 云顶新耀新型抗菌药物依嘉在中国台湾获批 近日，云顶新耀宣布，中国台湾地区药政部门已批准创新型强效抗菌药物依嘉（依拉环素）用于治疗复杂性腹腔内感染（cIAI）的新药上市许可申请。 云顶新耀曾于2022年与台湾东洋药品达成在中国台湾地区商业化依嘉的独家合作协议。台湾东洋药品是中国台湾地区最大的本土医药企业之一。 04 迈威生物Nectin-4 ADC联合PD-1抑制剂的Ib/II期临试完成首例给药 近日，迈威生物宣布，靶向Nectin-4的抗体偶联药物（ADC）9MW2821与PD-1抑制剂联合用药治疗局部晚期或转移性尿路上皮癌患者的Ib/II期临床试验完成首例患者给药。该临床试验（CTR20232677）旨在评估9MW2821联合PD-1抑制剂在局部晚期或转移性尿路上皮癌患者中的安全耐受性、初步疗效以及药代动力学特征。 企业动态 Companies 01 荣昌生物与康方生物探索开坦尼和爱地希联合用药 近日，荣昌生物宣布将携手康方生物（旗下子公司康方药业）推进康方生物独立自主研发的全球首款PD-1/CTLA-4双特异性抗体卡度尼利单抗注射液（商品名：开坦尼）与荣昌生物自主开发的中国首款国产抗体偶联药物注射用维迪西妥单抗（商品名：爱地希）的联合疗法的开发，并启动一项针对胃癌（含胃食管结合部腺癌）的Ⅱ期临床研究。 爱地希是由荣昌生物自主研发的我国首个获批上市的国产ADC新药，以肿瘤表面的HER2蛋白为靶点，能精准识别和杀伤肿瘤细胞，在治疗胃癌、尿路上皮癌、乳腺癌等多个瘤种的临床试验中表现优异，是我国首个获得美国FDA、中国国家药监局突破性疗法双重认定的ADC药物。 02 东软智睿NeuRT Aurora极光智慧放疗平台获批益 近日，东软智睿宣布，其创新研发的全新一代国产高端医用直线加速器NeuRT Aurora极光智慧放疗平台获得国家药品监督管理局批准上市。 NeuRT Aurora极光智慧放疗平台能够支持全球首创的螺旋容积调强（SVMAT）治疗，兼具螺旋断层（TOMO）和容积旋转调强（VMAT）的优势，能够达到更好的剂量分布和器官保护，同时提高疗效。 行业政策 Policies 01 北京23家医院试点双通道，医疗机构与协议药店统一支付标准 近日，北京市医保局发布《关于进一步做好国家医保谈判药品落地试点工作的通知》，将于10月28日起在本市药品“双通道”保障工作的基础上，选取部分门诊量大、国谈药采购数量少的23家定点医疗机构开展“双通道”管理试点工作。 02 2023年京津冀药品带量采购工作启动，人血白蛋白再入围 近日，北京市医保局发布《关于开展2023年京津冀药品带量采购有关工作的通知》，共37个药品入围，除化学药品外还有凝血因子、纤维蛋白原、人血白蛋白等生物制剂。取得药品注册证书的上市许可持有人并已获得国家医保编码的企业和药品（无严重违约/失信行为）原则上均可参加。 03 上海市提高基层用药支付比例 近日，上海市发布《本市医保进一步支持社区卫生服务能力提升的若干举措》的通知，将适度提高基层医疗机构的门急诊报销比例。 在基层医疗机构配备使用的医保目录内的乙类药品（定额标准自负药品除外），参照甲类药品支付。集中带量采购药品的支付政策按照有关规定执行。

9月28日，云顶新耀宣布中国台湾地区药政部门（TFDA）已批准创新型强效抗菌药依拉环素（商品名：依嘉）用于治疗成人复杂性腹腔内感染的新药上市许可申请（NDA）。 复杂性腹腔内感染（cIAI）是一种院内或社区获得性感染，是由空腔脏器延伸到腹膜腔形成的腹膜炎或者脓肿的感染疾病。cIAI包括腹腔脓肿、胃或肠穿孔、腹膜炎、阑尾炎、胆囊炎、憩室炎等。cIAI由不同的病原体引起，包括革兰阴性菌、革兰阳性菌和厌氧菌。 公开资料显示，依拉环素是一种新型、全合成、广谱、含氟四环素类、静脉注射抗菌药物，可用于包括在中国常见的革兰阴性菌、革兰阳性菌感染在内的多重耐药菌感染的一线经验性单药治疗。该药具有抗菌谱广、抗菌活性强、临床疗效确切及安全性好等优点。云顶新耀通过与Tetraphase公司达成授权协议，获得了该药在大中华区、韩国和部分东南亚主要市场（包括印度尼西亚、马来西亚、菲律宾、泰国、新加坡和越南）的开发和商业化独家权益。 据云顶新耀新闻稿介绍，依拉环素目前已在美国、欧盟、英国、新加坡、中国大陆、中国香港地区和中国台湾地区获批用于治疗复杂性腹腔内感染（cIAI）。2022年8月，云顶新耀宣布已与台湾东洋药品公司达成在中国台湾地区商业化依拉环素的独家合作协议。 云顶新耀首席执行官罗永庆先生表示，依拉环素在中国台湾地区的NDA获批具有重要意义，有望在该地区助力解决“无药可用”的多重耐药菌感染的治疗困境。依拉环素已经于今年7月在中国大陆成功实现商业化上市，他们将尽快在中国香港地区和中国台湾地区等地推出该产品，以挽救更多危重患者的生命。 参考资料：[1]云顶新耀宣布创新型强效抗菌药物依嘉®在中国台湾获批用于治疗成人复杂性腹腔内感染. Retrieved Sep 28， 2023, from https://mp.weixin.qq.com/s/4FCQNtN9HfgdBFOFUpwNAQ 内容来源于网络，如有侵权，请联系删除。